Parkinson's Foundation UK
Location	London, UK
Type	Charity/Research Organization
Founded	1969
Website	https://www.parkinsons.org.uk/
Focus Areas	Parkinson's Disease Research, Patient Support, Clinical Trials, Drug Discovery

Parkinson’s Foundation UK

Overview

Parkinson’s Foundation UK (formerly Parkinson’s UK) is the leading charity organization for Parkinson’s disease in the United Kingdom. Founded in 1969, the organization funds research, provides support and information for people affected by Parkinson’s, and campaigns for better services and care^{1Parkinson's UK Official WebsiteOpen reference}. With over 150,000 people living with Parkinson’s in the UK, the organization plays a critical role in advancing research and improving quality of life for patients and caregivers.

Parkinson’s Foundation UK funds groundbreaking research into the causes of Parkinson’s, new treatments, and ultimately a cure. The organization works closely with researchers, healthcare professionals, and people living with Parkinson’s to ensure research is focused on what matters most to patients^{2Parkinson's UK Research Strategy 2024-2029Open reference}. The organization’s research strategy emphasizes translational research that moves discoveries from the laboratory to clinical practice, with particular emphasis on:

• Understanding the underlying mechanisms of alpha-synuclein pathology

• Developing disease-modifying therapies

• Improving diagnostic biomarkers

• Enhancing quality of life for people with Parkinson’s

---

Research Programs

Cause Research

Understanding why Parkinson’s develops is fundamental to finding a cure. The organization funds research into:

Genetic Factors Research into inherited forms of Parkinson’s has identified key genes including LRRK2, GBA, SNCA, and PARKIN^{3Genetics of Parkinson's disease: state of the art and open questions2023 · Nature Reviews NeurologyOpen reference}. UK research has been particularly important in understanding the role of these genetic variants in different populations and in developing genetic testing approaches.

Environmental Factors Studies examine the role of environmental exposures including pesticides, traumatic brain injury, and lifestyle factors in Parkinson’s disease risk. The organization supports population-based studies and mechanistic research into how these factors may trigger neurodegeneration.

Alpha-Synuclein Biology The pathological accumulation of alpha-synuclein in Lewy bodies is a hallmark of Parkinson’s disease^{4Alpha-synuclein pathology in Parkinson's disease: From diagnosis to treatment2024 · BrainOpen reference}. Research funded by the organization examines the mechanisms of protein misfolding, aggregation, and propagation throughout the nervous system.

Treatment Development

New drug therapies represent the highest priority for Parkinson’s Foundation UK:

Disease-Modifying Therapies The organization funds research targeting key pathological processes including:

• Alpha-synuclein aggregation and spread

• Mitochondrial dysfunction

• Neuroinflammation Lysosomal dysfunction

Symptomatic Treatments Research improves existing treatments and develops new approaches for:

• Motor symptoms (tremor, bradykinesia, rigidity)

• Levodopa-induced complications^{5Levodopa and the pathogenesis of Parkinson disease2022 · Movement DisordersOpen reference}

• Non-motor symptoms

Deep Brain Stimulation Funding supports research into optimal targeting and programming of deep brain stimulation^{6Deep brain stimulation for Parkinson's disease2022 · Nature Reviews NeurologyOpen reference}, as well as development of closed-loop systems that adapt to patient needs.

Clinical Trials

The organization maintains a robust clinical trials infrastructure^{7Clinical Trials Infrastructure in the UKOpen reference}:

Trial Network Parkinson’s Foundation UK supports a network of clinical trials centers across the UK, enabling rapid recruitment for multi-center studies and ensuring geographic access to cutting-edge treatments.

Patient Engagement The organization ensures that clinical trials are designed with patient priorities in mind, improving recruitment and ensuring that trial outcomes matter to people with Parkinson’s.

Early Phase Studies Support for first-in-human studies and early phase clinical trials enables translation of basic science discoveries into clinical applications.

Care Research

Improving quality of life extends beyond drug therapies:

Non-Motor Symptoms Research addresses depression, anxiety, sleep disorders, constipation, and cognitive impairment that significantly impact quality of life^{8Non-motor symptoms of Parkinson's disease: Diagnosis and management2023 · Nature Reviews NeurologyOpen reference}.

Rehabilitation Studies examine the effectiveness of physical therapy, speech therapy, and occupational therapy interventions.

Caregiver Support Research examines the needs of caregivers and develops interventions to support family care networks.

---

Key Initiatives

Parkinson’s UK Drug Club

An innovative initiative bringing together researchers, pharmaceutical companies, and patients to accelerate drug development for Parkinson’s disease^{9Accelerating Drug Development for Parkinson'sOpen reference}. The Drug Club:

• Provides a forum for academic-industry collaboration

• Offers access to drug development expertise

• Facilitates sharing of compounds and resources

• Supports pre-competitive collaboration

Parkinson’s Clinical Studies

Supporting clinical trials from early phase to large-scale studies^{7Clinical Trials Infrastructure in the UKOpen reference}:

Phase I Trials First-in-human safety studies for novel therapeutic candidates.

Phase II Trials Proof-of-concept studies examining efficacy and dose-finding.

Phase III Trials Large-scale confirmatory trials for regulatory approval.

Observational Studies Longitudinal studies tracking disease progression and identifying biomarkers.

Biobanking Initiative

The organization maintains a biobank with samples from well-characterized patient cohorts:

• DNA samples for genetic studies

• Serum and CSF for biomarker research

• Tissue samples from brain banks

• Longitudinal clinical data

This resource enables research into disease mechanisms and biomarker discovery^{2Parkinson's UK Research Strategy 2024-2029Open reference}0.

---

Impact and Achievements

Research Funding

Parkinson’s Foundation UK has invested significantly in research:

• Annual Research Budget: Over £4 million annually

• Active Grants: 40+ research projects at any given time

• Fellowships: Supporting the next generation of Parkinson’s researchers

• International Collaboration: Partnership with Parkinson’s Foundation (US) and Parkinson’s Europe

Clinical Trials

The organization has supported numerous clinical studies:

• Contributed to trials leading to regulatory approval of new medications

• Enabled development of improved deep brain stimulation techniques

• Supported trials of disease-modifying therapies targeting alpha-synuclein

Patient Support

Beyond research, the organization provides:

• Information and Resources: Comprehensive guides for patients and caregivers

• Helpline: Professional support and advice

• Local Networks: Support groups across the UK

• Advocacy: Campaigning for improved services and care

---

Research Priorities 2024-2029

The current research strategy^{2Parkinson's UK Research Strategy 2024-2029Open reference}1 focuses on:

1. Understanding Parkinson’s: Funding basic science to understand disease mechanisms

2. Earlier Diagnosis: Developing biomarkers for preclinical detection

3. Better Treatments: Creating new therapies that modify disease progression

4. Improved Care: Enhancing quality of life through better support and services

---

Collaborative Networks

European Collaboration

Parkinson’s Foundation UK works closely with Parkinson’s Europe to advance research across the continent^{2Parkinson's UK Research Strategy 2024-2029Open reference}2:

• Shared funding of pan-European studies

• Coordination of clinical trial networks

• Joint advocacy for research funding

International Partnerships

The organization maintains relationships with:

• Parkinson’s Foundation (US)

• Michael J. Fox Foundation

• Cure Parkinson’s

• European Parkinson’s Disease Association

UK Research Infrastructure

Collaboration with:

• UK Biobank: Access to large-scale genetic and health data^{2Parkinson's UK Research Strategy 2024-2029Open reference}3

• NIHR Biomedical Research Centers

• University research departments

---

Future Directions

Emerging Research Areas

The organization is increasingly focused on:

Precision Medicine Tailoring treatments to individual patients based on genetic profile, disease subtype, and biomarker status.

Alpha-Synuclein Targeting Supporting development of antibodies, small molecules, and gene therapies targeting the pathological protein^{2Parkinson's UK Research Strategy 2024-2029Open reference}4.

Neuroprotection Identifying and testing compounds that can protect neurons from degeneration.

Stem Cell Therapies Supporting research into cell replacement approaches.

Research Infrastructure Development

• Expanding clinical trial capacity

• Enhancing biobank resources

• Developing biomarker validation facilities

• Creating data platforms for research collaboration

---

External Links

• Official Website: Parkinson’s UK

• Research: https://www.parkinsons.org.uk/research

• Clinical Trials: https://www.parkinsons.org.uk/research/clinical-trials

• Drug Club: https://www.parkinsons.org.uk/research/drug-club

---

See Also

• Parkinson’s Disease

• Alpha-Synuclein

• LRRK2

• Michael J. Fox Foundation

• Cure Parkinson’s

• Deep Brain Stimulation

• Non-Motor Symptoms of Parkinson’s

---